Skip to main content

Atara Biotherapeutics, Inc.

ATRA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001604464

In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.

Q1 2024 vs. Q4 2023

How the institutions holding Atara Biotherapeutics, Inc. changed between Q4 2023 and Q1 2024.

All holders in Q1 2024All holders in Q4 2023

13F holders of ATRA: Q4 2023 compared with Q1 2024
MeasureQ4 2023Q1 2024Change
Holders9182−9
Shares64.7M83.3M+18.5M (+28.7%)
Value$33.2M$57.8M+$24.6M (+74.1%)

New holders (16)

Institutions that held Atara Biotherapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.

Institutions new to ATRA in Q1 2024
InstitutionSharesValue% of portfolio
Boxer Capital, LLC4,150,000$2.88M0.14%
Vestal Point Capital, LP2,800,000$1.94M0.16%
Tang Capital Management LLC1,879,923$1.30M0.14%
Woodline Partners LP1,774,802$1.23M0.01%
J. Goldman & Co LP986,651$684.7K0.03%
Checkpoint Capital L.P.892,853$619.6K0.41%
Shay Capital LLC438,506$304.3K0.09%
TD Asset Management Inc436,800$303.1K0.00%
Schonfeld Strategic Advisors LLC147,000$102.0K0.00%
Savant Capital, LLC131,811$91.5K0.00%
Delap Wealth Advisory, LLC41,533$28.8K0.01%
Atom Investors LP31,408$21.8K0.00%
JustInvest LLC13,401$9.30K0.00%
HSBC Holdings PLC11,264$7.82K0.00%
Nelson, Van Denburg & Campbell Wealth Management Group, LLC23$150.00%
Capital Advisors, Ltd. LLC396$00.00%

Sold out (25)

Institutions that held Atara Biotherapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.